Employees: 1-10
Investment Type: Venture Capital
Investment Stage: Series B; Series C
Portfolio 24
| Date | Name | Website | Total Raised | Location |
| 22.10.2021 | Click Ther... | clicktherapeutics.com | $119M | United Sta... |
| 23.10.2020 | Orbus Ther... | orbustherapeutics.com | $103.5M | Canada |
| 03.01.2017 | Intact Vas... | intactvascular.com | $145.5M | United Sta... |
| 09.08.2016 | Iconic The... | iconictherapeutics.com | $108.5M | United Sta... |
| - | Arvelle Th... | arvelletx.com | - | Switzerlan... |
| - | Taconic Bi... | taconic.com | - | United Sta... |
| - | NeuWave Me... | neuwavemedical.com | $19.5M | United Sta... |
| - | ForSight V... | forsightv5.com | $15M | - |
| - | Salmedix | treanda.com | - | - |
| - | Leiters | leiters.com | - | United Sta... |
Show more
Mentions in press and media 19
| Date | Title | Description |
| 02.03.2022 | H.I.G. Capital Expands BioHealth Team with Addition of Gwen Watanabe | STAMFORD – March 2, 2022 – H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $47 billion of equity capital under management, is pleased to announce that Gwen Watanabe has joined the firm’s dedicated life-scie... |
| 26.10.2021 | H.I.G. BioHealth Partners Co-Leads a $52M Financing for Click Therapeutics | STAMFORD, CT – October 26, 2021 - H.I.G. BioHealth Partners (“H.I.G.”), the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global alternative investment firm with over $45 billion of equity capital under management,*... |
| 15.02.2019 | Axovant spin-off launched in Basel with an initial funding of over CHF100m | |
| 14.03.2018 | On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn | WEST LAFAYETTE, Ind. 14 March 2018 – On Target Laboratories, Inc., a privately-held biotechnology company that is developing tumour-targeted fluorescent dyes to improve cancer surgery, has secured additional financing as part of its Serie... |
| 14.03.2018 | H.I.G. Joins Funding Round for On Target Labs | On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, has secured an additional financing as part of its Series B capital raise which initially clo... |
| 14.05.2015 | Intact Vascular Raises $38.9M in Series B VC Financing | Intact Vascular, Inc., a Wayne, Pa.-based developer of medical devices for minimally invasive peripheral vascular procedures, raised $38.9m in Series B venture capital financing. The round was led by New Enterprise Associates (NEA), with pa... |
| 16.04.2014 | ForSight VISION5 Sees $15M Series C Funding | MENLO PARK, CA, ForSight VISION5 has completed its Series C financing which raised $15 million and was led by H.I.G. BioVentures. >> Click here for more funding data on ForSight VISION5 >> To export ForSight VISION5 funding ... |
| 16.04.2014 | Iconic Therapeutics Completes $20M Series B-1 Equity Financing | Iconic Therapeutics, Inc., a Atlanta, GA and South San Francisco, CA-based biotechnology company focused on developing therapeutics for serious eye disorders, completed a $20m Series B-1 equity financing. Backers included new investors MPM ... |
| 16.04.2014 | ForSight VISION5 Completes $15M Series C Financing | ForSight VISION5, a Menlo Park, CA-based developer of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy, completed a $15m Series C finan... |
| 23.12.2013 | Medical device maker nets $4.7M to tackle peripheral artery disease complications | The Wayne, Pa.-based company has raised about $4.7 million from five investors, according to a document filed with the Securities and Exchange Commission. Among its investors are Quaker Partners and H.I.G. BioVentures, as well as angel inve... |
Show more